General Information of Drug Transporter (DT)
DT ID	DTD0084 Transporter Info
Gene Name	SLC12A3
Protein Name	Thiazide-sensitive sodium-chloride cotransporter
Gene ID	6559
UniProt ID	P55017
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs13306673
Site of GPD	chr16:56867019 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1488/745 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Thiazides, Plain	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased reduction in mean blood pressure when treated with Thiazides, plain in people with Essential hypertension as compared to genotypes CT + TT.		[ 1]
Thiazides, Plain	N.A.	Essential Hypertension	Genotype CC is associated with increased reduction in mean blood pressure when treated with Thiazides, plain in people with Essential hypertension as compared to genotypes CT + TT.		[ 1]
Thiazides	N.A.	Essential Hypertension	Correlated with the increased reduction in mean blood pressure in patients (compare with Genotypes CT + TT)		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Thiazides, Plain	N.A.	Essential Hypertension	Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Thiazides, Plain	N.A.	Essential Hypertension	Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.		[ 1]
Genetic Polymorphism	rs1529927
Site of GPD	chr16:56870675 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.0094/47 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Torsemide	Drug Info	Healthy Individuals	Correlated with the increased 24-h excretion of chloride and potassium in healthy individuals (compare with Allele G)		[ 2]
Furosemide	Drug Info	Healthy Individuals	Correlated with the increased 24-h excretion of chloride and potassium in healthy individuals (compare with Allele G)		[ 2]
Bumetanide	Drug Info	Healthy Individuals	Correlated with the increased 24-h excretion of chloride and potassium in healthy individuals (compare with Allele G)		[ 2]
Bumetanide	N.A.	Colorectal Neoplasms	Allele C is associated with increased 24-h excretion of chloride and potassium when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele G.		[ 2]
Furosemide	N.A.	Colorectal Neoplasms	Allele C is associated with increased 24-h excretion of chloride and potassium when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele G.		[ 2]
Torasemide	N.A.	Colorectal Neoplasms	Allele C is associated with increased 24-h excretion of chloride and potassium when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele G.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Torsemide	Drug Info	Healthy Individuals	Correlated with the increased drug response in healthy individuals (compare with genotype GG)		[ 3]
Furosemide	Drug Info	Healthy Individuals	Correlated with the increased drug response in healthy individuals (compare with genotype GG)		[ 3]
Bumetanide	Drug Info	Healthy Individuals	Correlated with the increased drug response in healthy individuals (compare with genotype GG)		[ 3]
Bumetanide	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.		[ 3]
Furosemide	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.		[ 3]
Torasemide	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.		[ 3]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Bumetanide	N.A.	Colorectal Neoplasms	Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
Furosemide	N.A.	Colorectal Neoplasms	Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
Torasemide	N.A.	Colorectal Neoplasms	Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Bumetanide	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
Furosemide	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
Torasemide	N.A.	Colorectal Neoplasms	Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.		[ 3]
References
1	The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertens Res. 2004 Nov;27(11):821-33.
2	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
3	The genetics of loop diuretic effects. Pharmacogenomics J. 2012 Feb;12(1):45-53.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.